ReviewCancers2025
Small Nucleolar RNAs as Emerging Players in Cancer Biology and Precision Medicine.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- SnoRNA and SNHG in Bladder Cancer: Molecular Mechanisms and Clinical Significance.Current issues in molecular biology · 2026Review
- RRP9 suppresses hepatocellular carcinoma progression by inhibiting the PI3K/AKT/mTOR pathway.International journal of oncology · 2026Article
- Non-coding RNAs as regulators of chromosomal instability in breast cancer.Frontiers in oncology · 2026Review
- Serum small extracellular vesicle-associated snoRNA panel adds diagnostic value to CEA and CYFRA21-1 for non-small cell lung cancer: an exploratory single-center study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small nucleolar RNAs (snoRNAs) constitute a class of non-coding RNAs traditionally associated with ribosomal RNA modification. However, recent research has revealed that these molecules participate in a wide range of cellular processes with significant implications for cancer biology. This review examines the emerging evidence on snoRNA dysregulation in various tumor types, where they can function as both oncogenes and tumor suppressors. We analyze the multiple molecular mechanisms through which snoRNAs contribute to malignant transformation, including the generation of specialized ribosomes, alternative splicing regulation, epigenetic modulation, and post-transcriptional regulatory functions. We discuss the potential of snoRNAs as non-invasive biomarkers for cancer diagnosis and prognosis, as well as emerging strategies for their utilization as therapeutic targets. The integration of these findings positions snoRNAs as fundamental players in oncogenesis and opens new avenues for the development of clinical tools in precision cancer medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.